Compare ETD & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETD | ABCL |
|---|---|---|
| Founded | 1932 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.7M | 1.3B |
| IPO Year | 1996 | 2020 |
| Metric | ETD | ABCL |
|---|---|---|
| Price | $20.55 | $5.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $27.00 | $8.40 |
| AVG Volume (30 Days) | 463.5K | ★ 8.4M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 8.15% | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ 1.10 | N/A |
| Revenue | ★ $766,784,000.00 | $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.73 | $21.85 |
| P/E Ratio | $18.58 | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $18.28 | $2.33 |
| 52 Week High | $31.41 | $6.79 |
| Indicator | ETD | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 49.42 | 59.45 |
| Support Level | $18.28 | $5.34 |
| Resistance Level | $22.89 | $6.52 |
| Average True Range (ATR) | 0.52 | 0.47 |
| MACD | 0.20 | 0.10 |
| Stochastic Oscillator | 67.20 | 59.38 |
Ethan Allen Interiors Inc through its subsidiaries, operates as an interior design company, and a manufacturer and retailer in the home furnishings marketplace. Its product offerings include fabric chairs, beds, wallpapers, desks, and dining tables among others. The company's reportable segments are; Wholesale and Retail. The Wholesale segment is principally involved in the development of the Ethan Allen brand and encompasses all aspects of design, manufacturing, sourcing, marketing, sale, and distribution of home furnishings and accents. The Retail segment which generates maximum revenue, sells home furnishings and accents to clients through company-operated design centers. Geographically, it derives key revenue from the United States and the rest from other regions.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.